Lonza’s bYlok® technology is changing the way bispecific antibodies are designed. Achieving the correct heterodimerization of light and heavy chains during bispecific production can be challenging, ...

Light chain multiple myeloma (LCMM) is so-called because the myeloma cells are only able to produce the light chain protein and cannot produce the heavy chain protein.

Lonza’s bYlok® technology is changing the way bispecific antibodies are designed. Achieving the correct heterodimerization of light and heavy chains during bispecific production can be challenging, ...